Citations

Clear

813 citation(s) found for "He, Helen".

Lifetime Risk of First Symptomatic ICH or Seizure in Familial Cerebral Cavernous Malformations
Dammann, Philipp , Santos, Alejandro N. , Mavarani, Laven , Chabriat, Hugues , Croft, Jacob , Renteria, Mellisa, Jang, David, Zhang, Jun , Li, Da , Weng, Jiancong , Pilz, Robin A. , Felbor, Ute , Steinberg, Gary K. , Bervini, David , Raabe, Andreas , Rosales, Julieta , Rieß, Christoph , Karadachi, Hannah, Li, Yan , Köhrmann, Martin, Frank, Benedikt , Schmidt, Börge , Overstijns, Manou , Fung, Christian , Zafar, Atif , Nelson, Jeffrey , Zabramski, Joseph M. , Akers, Amy , Kim, Helen , Guey, Stéphanie , Chabriat, Hugues , Herve, Dominique , Zhang, Jun , Weng, Jian-Cong , Rath, Matthias , Steinberg, Gary K , Bervini, David , Rauschenbach, Laurèl , Jabbarli, Ramazan , Beck, Jürgen , Fung, Christian , Al-Shahi Salman, Rustam , Flemming, Kelly D , Lanzino, Giuseppe , Morrison, Leslie , Kim, Helen , Sure, Ulrich , Karadachi, Hanah Hadice , Santos, Alejandro N. , Guey, Stéphanie , Wu, Zhenhua , Petracca, Antonio , Fusco, Carmela , D’Agruma, Leonardo , Castori, Marco , Gu, Jing , Goldberg, Johannes , Cervio, Andrés , Villamil, Facundo , Rauschenbach, Laurèl , Oppong, Marvin Darkwah , Ahmadipour, Yahya , Wrede, Karsten Henning , Jabbarli, Ramazan , Deuschl, Cornelius , Piedade, Guilherme Santos , Wälchli, Thomas , Salman, Rustam Al‐Shahi , Flemming, Kelly D. , Lanzino, Giuseppe , Weinsheimer, Shantel , McCulloch, Charles E. , Sure, Ulrich

Mayo Clinic

Neurology | July 10, 2025 | Volume: 105 | Issue: 3 | Pages: No page available

10.1212/wnl.0000000000213798 | PMID 40638881 Get It

NCCN Guidelines® Insights: Thyroid Carcinoma, Version 1.2025
Haddad, Robert I. , Bischoff, Lindsay , Applewhite, Megan K. , Bernet, Victor , Blomain, Erik , Brito, Maria , Busaidy, Naifa L. , Campbell, Michael J. , DeLozier, Olivia M. , Duh, Quan‐Yang , Ehya, Hormoz, Grady, Erin C., Hunt, Jason P. , Kandeel, Fouad , Lamonica, Dominick , Lorch, Jochen H. , Mandel, Susan J., Mydlarz, Wojciech K. , Raeburn, Christopher D., Rezaee, Rod , Ritter, Hadley E., Roth, Mara Y. , Salgado, Sarimar Agosto , Scheri, Randall P., Sipos, Jennifer A. , Wirth, Lori J. , Darlow, Susan, Cassara, Carly J., Sliker, Bailee , Haddad, Robert , Guo, Theresa , Haymart, Megan R. , Kotwal, Anupam , Markovina, Stephanie T. , Nabell, Lisle M. , Ridge, John Andrew , Shah, Jatin P. , Sippel, Rebecca S. , Sturgeon, Cord , Wong, Richard J. , Worden, Francis P. , Yeh, Michael W.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | July 10, 2025 | Volume: 23 | Issue: 7 | Pages: No page available

10.6004/jnccn.2025.0033 | PMID 40639400 Get It

The NCCN Guidelines for Thyroid Carcinoma address the management of different types of thyroid carcinoma, including papillary, follicular, oncocytic, medullary, and anaplastic carcinoma. The NCCN Thyroid Carcinoma Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. These NCCN Guidelines Insights focus on the panel’s most recent recommendations regarding systemic therapies for thyroid carcinoma as well as the supporting clinical data.
Identifying features of prior hemorrhage in cerebral cavernous malformations on quantitative susceptibility maps: a machine learning pilot study
Kinkade, Serena , Li, Hui , Stadnik, Agnieszka , Papaioannou, John , Kim, Helen , Torbey, Michel , Awad, Issam A., Kim, Helen , Hage, Stephanie , Koskimäki, Janne , Lee, Justine C. , Shenkar, Robert , Flemming, Kelly D. , Huang, Judy , Carroll, Timothy , Girard, Romuald , Giger, Maryellen , Awad, Issam A.

Mayo Clinic

Journal of Neurosurgery | July 4, 2025 | Volume: 143 | Issue: 6 | Pages: 1567-1574

10.3171/2025.3.jns243051 | PMID 40614265 Get It

Features of new bleeding on conventional imaging in cerebral cavernous malformations (CCMs) often disappear after several weeks, yet the risk of rebleeding persists long thereafter. Increases in mean lesional quantitative susceptibility mapping (QSM) ≥ 6% on MRI during 1 year of prospective surveillance have been associated with new symptomatic hemorrhage (SH) during that period. The authors hypothesized that QSM at a single time point reflects features of hemorrhage in the prior year or potential bleeding in the subsequent year. Twenty-eight features were extracted from 265 QSM acquisitions in 120 patients enrolled in a prospective trial readiness project, and machine learning methods examined associations with SH and biomarker bleed (QSM increase ≥ 6%) in prior and subsequent years. QSM features including sum variance, variance, and correlation had lower average values in lesions with SH in the prior year (p < 0.05, false discovery rate corrected). A support-vector machine classifier recurrently selected sum average, mean lesional QSM, sphericity, and margin sharpness features to distinguish biomarker bleeds in the prior year (area under the curve = 0.61, 95% CI 0.52–0.70; p = 0.02). No QSM features were associated with a subsequent bleed. These results provide proof of concept that machine learning may derive features of QSM reflecting prior hemorrhagic activity, meriting further investigation. Clinical trial registration no.: NCT03652181 ( ClinicalTrials.gov )
462 Powering Precision Medical Education Through AI-Generated Country-Specific Global Surgery Podcasts: A Low-or-Middle-Income-Country Case Study
Please, Helen , Nsubuga, Moses Luutu , Kintu, Timothy , Bakesiga, Allan , Stewart, Kathleen , Nsubuga, Mike , Stewart, K, Navarro, Sergio M.

Mayo Clinic

British Journal of Surgery | June 26, 2025 | Volume: 112 | Issue: Supplement_10 | Pages: No page available

10.1093/bjs/znaf128.052 Get It

Abstract Aim Develop an AI-generated Global Surgery podcast series tailored to healthcare professionals’ needs in specific countries, focussing on Uganda as a pilot. This precision education model addresses disparities in global surgical education, historically driven by high-income countries (HICs). Podcasts were chosen for their scalability, accessibility, and self-directed learning. Method Building on prior data from our international trainee-based needs assessment (145 survey respondents from 18 countries; 94 from Low-and-Middle-Income-Countries, LMICs; 51 from High-Income-Countries, HICs). Generative AI (ChatGPT 4.0, OpenAI) and prompt engineering were used to develop a global surgery curriculum from survey data from Ugandan respondents (selected because Uganda had one of the highest response rates, n=31). The resultant curriculum was then adapted into a podcast format featuring country-specific themes using NotebookLM (Google), using a format of exercises, case studies, and expert interviews. Results The preliminary outputs of the survey and podcasts highlight diverse country-specific priorities; for HICs these include access to resources, research opportunities, and infrastructure development; for LMICs they emphasise the burden of surgical disease, use of local case studies, and foundational concepts in global surgery. Conclusions By tailoring content to regional needs and leveraging storytelling to foster engagement, podcasts can complement traditional curricula to address gaps in access and relevance. Limitations include current AI-generative software offering only US accents, which may not suit learners elsewhere, reflecting concerns about HICs bias in AI-generated content. Future research will validate the podcasts through focus groups with Ugandan surgical trainees, and explore speech-processing for regional accents, or blending human voice with AI-generated transcripts.
A curriculum for epilepsy surgery: A report from the Surgical Commission's Epilepsy Surgery Educational Task Force and the Educational Council of the ILAE
Dorfer, Christian , Enslin, Nico , Olivera, Tatiana von Hertwig Fernandes de, Wiebe, Samuel , Alotaibi, Faisal , Ali, Rushna , Englot, Dario J. , Cross, J. Helen , Ali, Rushna P, Dorfer, Christian , Englot, Dario J , Cross, Helen J , Nico Enslin, Johannes M , Muh, Carrie R. , Wang, Xiongfei , Wiebe, Samuel , McKhann, Guy M. , Damisah, Eyiyemisi C. , Singh, Gagandeep , Blümcke, Ingmar , Rydenhag, Bertil , Alonso‐Vanegas, Mario , Cukiert, Arthur

Mayo Clinic

Epileptic Disorders | June 26, 2025 | Volume: 27 | Issue: 5 | Pages: 718-728

10.1002/epd2.70054 | PMID 40569634 Get It

Abstract Objective There is a need to develop a comprehensive, formalized, and globally applicable epilepsy surgery curriculum in order to help standardize the quality of epilepsy surgery practice in the world. Methods The Epilepsy Surgery Educational Task Force of the ILAE developed a competency‐based epilepsy surgery educational curriculum comprised of four domains: Diagnosis, Counseling, Pre‐surgical Work‐up, and Surgical Techniques. To evaluate this educational curriculum, a survey questionnaire consisting of 11 items was sent out for feedback to ILAE and IESS members. The survey questionnaire asked respondents to rate the degree of importance of each competency on a five‐point scale that ranged from “extremely important” to “not at all important” and provided space for free text comments. All competencies that were rated as “slightly important” or “somewhat important” by more than 10% of responders, as well as all free text feedback comments, were fully reviewed, and the final curriculum was adjusted accordingly. Results One hundred and twenty‐two responses ( n = 122) were submitted by the ILAE and IESS communities. Seventy‐one percent (71.9%) of the responses came from neurosurgeons of varied experience and training levels. Ninety‐four percent (94.4%) of responders stated that they “support a curriculum to determine the competency of neurosurgeons participating in the care of people with epilepsy in my country,” and 94.3% confirmed that they “would be interested in taking or would recommend an ILAE course based on these competencies, that would provide an ILAE certificate of completion.” Relevant changes within the curriculum were made based on feedback. Significance The newly developed ILAE comprehensive epilepsy surgery educational curriculum has a high level of support from neurosurgeons and neurologists around the world and shows potential for broad acceptance and implementation.
419 | MULTICENTER REAL‐WORLD OUTCOMES IN DIFFUSE LARGE B‐CELL LYMPHOMA PROFILED WITH A COMMERCIALLY‐AVAILABLE CIRCULATING TUMOR DNA ASSAY
Gould, P., Ma, Xin , Ananth, Sudha , Rose, Alan, Lattin, John , Skarbnik, Alan P , Bock, Allison M. , Baron, Kelly Glazer , Hess, Brian , Ayers, Edward L., Pro, Barbara, Vaidya, S., Amengual, Jennifer E. , Godbole, S., Bond, David A. , Ananth, S., Jacobs, Ryan W. , Hu, Bei , Stanchina, Michele , Rose, A., Russler‐Germain, David A. , Randall, Michael P. , Spinner, Michael A. , Duarte, C., Major, Ajay , Baron, K., Ip, Andrew , Tsang, Mazie , Ayers, E., Tolu, Seda , Reshef, Ran , Cherng, Hua‐Jay J.

Mayo Clinic

Hematological Oncology | June 16, 2025 | Volume: 43 | Issue: S3 | Pages: No page available

10.1002/hon.70094_419 Get It

NCCN Guidelines® Insights: Survivorship, Version 2.2025
Sanft, Tara , Ansbaugh, Shannon M., Ariza‐Heredia, Ella , Ballinger, Tarah J. , Cohen, Stuart H. , Fairman, Nathan, Feliciano, Josephine , Flores, Tessa , Gabel, Nicolette , Goldman, Mindy, Hill‐Kayser, Christine E. , Hock, Karen , Kline‐Quiroz, Cristina , Koura, Divya, McDonough, Allison L. , Mooney, Kathi , Moryl, Natalie , Neuman, Heather B. , Patel, Chirayu G. , Peterson, Lindsay L. , Porpiglia, Andrea S., Saidain, Ava, Schapira, Lidia , Tenne, Laura, Ah, Diane Von , Zee, Phyllis C. , McMillian, Nicole R., Freedman-Cass, Deborah A., Tevaarwerk, Amyé , Ballinger, Tarah Jean , Day, Andrew T. , Armenian, Saro H. , Baker, Kevin Scott , Cathcart-Rake, Elizabeth , Evgeniou, Evgenios , Friedman, Debra L. , Lee, Nita Karnik , Moore, Halle C. F. , Overholser, Linda , Pirl, William F. , Rogers, Laura Q. , Smith, Sophia K. , Yang, Eric H. , Ah, Diane Von

Mayo Clinic

Journal of the National Comprehensive Cancer Network | June 11, 2025 | Volume: 23 | Issue: 6 | Pages: 208-217

10.6004/jnccn.2025.0028 | PMID 40499584 Get It

The NCCN Guidelines for Survivorship include screening, evaluation, and treatment recommendations for common physical and psychosocial problems resulting from adult-onset cancer and its treatment and provide a framework for coordination of survivorship care. They also include recommendations to help cancer survivors enhance their wellness and maintain a healthy lifestyle. These NCCN Guidelines Insights summarize the panel’s current recommendations and recent updates regarding physical activity, nutrition, and weight management for cancer survivors.
Predicting therapeutic clinical trial enrollment for adult patients with low- and high-grade glioma using supervised machine learning
Mehari, Mulki , Warrier, Gayathri , Dada, Abraham , Kabir, Aymen , Haskell-Mendoza, Aden , Tripathy, Arushi , Jha, Rohan , Nieblas‐Bedolla, Edwin , Jackson, Joshua , Gonzalez, Ariel T , Reason, Ellery , Flusché, Ann Marie , Reihl, Sheantel , Dalton, Tara , Negussie, Mikias , Gonzales, Cesar Nava, Ambati, Vardhaan , Desjardins, Annick , Krishna, Saritha, Chang, Susan M. , Porter, Alyx B. , Fecci, Peter E. , Hollon, Todd , Chukwueke, Ugonma , Badal, Kimberly , Molinaro, Annette M. , Hervey‐Jumper, Shawn L. , Haskell-Mendoza, Aden P , Reason, Ellery H , Ambati, Vardhaan , Krishna, Saritha , Porter, Alyx , Hollon, Todd , Chukwueke, Ugonma N , Badal, Kimberly , Molinaro, Annette M. , Hervey-Jumper, Shawn L , Reihl, Sheantel J , Fecci, Peter E , Desjardins, Annick , Daniel, Andy G. S.

Mayo Clinic

Science Advances | June 11, 2025 | Volume: 11 | Issue: 23 | Pages: No page available

10.1126/sciadv.adt5708 | PMID 40465719 Get It

Therapeutic clinical trial enrollment does not match glioma incidence across demographics. Traditional statistical methods have identified independent predictors of trial enrollment; however, our understanding of the interactions between these factors remains limited. To test the interactive effects of demographic, socioeconomic, and oncologic variables on trial enrollment, we designed boosted neural networks (BNNs) for all glioma patients ( n = 1042), women ( n = 445, 42.7%), and minorities ( n = 151, 14.5%) and externally validated these models [whole cohort, n = 230; women, n = 89 (38.7%); minority, n = 66 (28.7%)]. For the whole-cohort BNN, the most influential variables on enrollment were oncologic variables, including KPS [total effect (TE), 0.327], chemotherapy (TE, 0.326), tumor location (TE, 0.322), and seizures (TE, 0.239). The women-only BNN exhibited a similar trend. Conversely, for the minority-only BNN, socioeconomic variables [insurance status (TE, 0.213), occupation classification (TE, 0.204), and employment status (TE, 0.150)] were most influential. These results may help prioritize patient-specific initiatives to increase accrual.
Thymomas and Thymic Carcinomas, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
Riely, Gregory J. , Wood, Douglas E. , Aisner, Dara L. , Akerley, Wallace , Bauman, Jessica R. , DeCamp, Malcolm M., Desai, Aakash , Dilling, Thomas J. , Durm, Gregory A. , Gettinger, Scott , Gubens, Matthew A. , Lackner, Rudy P., Maldonado, Fabien , Morgensztern, Daniel , Mullikin, Trey C. , Ng, Thomas, Owen, Dawn , Patel, Sandip Pravin , Riess, Jonathan W. , Shapiro, Theresa A. , Singh, Aditi P. , Stevenson, James, Tam, Alda L. , Yang, Stephen C. , Yau, Edwin , Gregory, Kristina M., Hang, Lisa, Desai, Aakash P , Loo, Billy W. , Bharat, Ankit , Chang, Joe Y. , Chirieac, Lucian R. , Dowell, Jonathan E. , Grotz, Travis E. , Juloori, Aditya , Lanuti, Michael D. , Lin, Jules , Lovly, Christine Marie , Owen, Dwight H , Patil, Tejas , Polanco, Patricio Marcelo , Tanvetyanon, Tawee , Yanagawa, Jane

Mayo Clinic

Journal of the National Comprehensive Cancer Network | June 11, 2025 | Volume: 23 | Issue: 6 | Pages: 255-269

10.6004/jnccn.2025.0027 | PMID 40499586 Get It

Thymomas and thymic carcinomas are rare mediastinal tumors that originate in the thymus. Patients with thymoma may experience symptoms associated with autoimmune paraneoplastic diseases (such as myasthenia gravis), which typically do not occur in patients with thymic carcinoma. The NCCN Guidelines for Thymomas and Thymic Carcinomas provide guidance for the diagnosis, treatment, and surveillance of patients with thymoma and thymic carcinoma. Involvement of a multidisciplinary team with experience treating thymomas and thymic carcinomas is highly recommended.
Phase II (Alliance A091802) Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma
Zandberg, Dan P. , Allred, Jacob B., Rosenberg, Ari J. , Swiecicki, Paul , Julian, Ricklie , Poklepovic, Andrew , Bauman, Jessica R. , Saba, Nabil F. , Rivera, Edgardo, Rowland, Kendrith M. , Cordes, Julia, Münster, Pamela N. , Swiecicki, Paul Loren , Poklepovic, Andrew S , Bauman, Jessica R , Saba, Nabil F , Davar, Diwakar , Ho, Alan L , Berg, Stephanie A , Schwartz, Gary K , Munster, Pamela , Kaczmar, John M. , Phan, Minh D., Davar, Diwakar , Cordes, Julia, Ho, Alan L. , Zhang, Miao , Berg, Stephanie , Schwartz, Gary K.

Mayo Clinic

Journal of Clinical Oncology | May 31, 2025 | Volume: 43 | Issue: 21 | Pages: 2398-2408

10.1200/jco-25-00759 | PMID 40448574 Get It

PURPOSE Continued improvement in outcomes is needed for advanced cutaneous squamous cell carcinoma (cSCC). Methods Alliance A091802 is a randomized phase II trial of avelumab (800 mg IV once every 2 weeks) plus cetuximab (500 mg/m 2 IV once every 2 weeks) versus avelumab alone once every 2 weeks for up to 2 years. Cetuximab was given for 1 year in the avelumab + cetuximab arm. Crossover at progression to avelumab + cetuximab was allowed. Randomization was 1:1, stratified by PD-L1 and HIV status. Patients had distant metastatic or unresectable locally advanced cSCC, were anti–PD-1/PD-L1 monoclonal antibody–naive, had no previous cetuximab in the advanced setting, had an Eastern Cooperative Oncology Group performance status of 0-2, and could be HIV+ (CD4 >200, viral load <200). Patients with chronic lymphocytic leukemia, immunosuppression, or active autoimmune diseases were excluded. The primary end point was progression-free survival (PFS; null hypothesis: median = 12 months v alternative hypothesis: 21 months or a 75% improvement, power of 80% with one-sided alpha .2, n = 57, 37 PFS events required). Secondary end points were overall survival, objective response rates (ORRs), clinical benefit rate, and toxicity. RESULTS Sixty patients were enrolled; 57 patients were evaluable. The median age was 72 years, all were HIV–; 75.4% was PD-L1+, 84.2% had head/neck origin, 47.4% had distant metastasis, and there were no differences in baseline characteristics by arm. Avelumab + cetuximab significantly improved PFS versus avelumab (median, 11.1 [7.6-not reached (NR)] v 3.0 months [2.7-13.6] hazard ratio, 0.48 [95% CI, 0.23 to 0.97], P = .018). Avelumab patients who crossed over (n = 9) to combination had a median PFS after crossover of 11.3 months (5.8-NR). The confirmed ORR was 27.6% with avelumab + cetuximab and 21.4% with avelumab. Grade 3 treatment-related adverse events occurred in 48.3% and 21.5% of patients with avelumab + cetuximab (most common: rash [20.7%], infusion reaction [20.7%]) and avelumab, respectively. CONCLUSION Avelumab + cetuximab significantly improved PFS versus avelumab alone in patients with advanced cSCC. Alliance A091802 supports a larger confirmatory study with the combination of cetuximab and PD-1:PD-(L)1 blockade.